Patents by Inventor Bruce A. Lee

Bruce A. Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Assays for detection of Bacillus anthracis
    Patent number: 6828110
    Abstract: This invention provides novel methods, reagents, and kits that are useful for detecting B. anthracis. The methods are based on the discovery of binding agents, including recombinant polyclonal antibodies, which bind to the surface array protein of B. anthracis.
    Type: Grant
    Filed: January 4, 2001
    Date of Patent: December 7, 2004
    Assignee: Biosite Incorporated
    Inventors: Bruce A. Lee, Becky Mar Flores, Gunars E. Valkirs
  • ASSAYS FOR DETECTION OF BACILLUS ANTHRACIS
    Publication number: 20040170967
    Abstract: This invention provides novel methods, reagents, and kits that are useful for detecting B. anthracis. The methods are based on the discovery of binding agents, including recombinant polyclonal antibodies, which bind to the surface array protein of B. anthracis.
    Type: Application
    Filed: January 4, 2001
    Publication date: September 2, 2004
    Inventors: Bruce A. Lee, Becky Mar Flores, Gunars E. Valkirs
  • Fivemer cyclic peptide inhibitors of diseases involving .alpha..sub.v .beta..sub.3
    Patent number: 5780426
    Abstract: The present invention includes non-RGD cyclic peptides that inhibit the function of the integrin receptor, .alpha..sub.v .beta..sub.3. The inventive peptides are between five to about thirty amino acids in length and include the sequence (SEQ ID NO:8), Arg-Cys-Asp-Gly-X.sub.i where X.sub.i is any amino acid, and a five-membered cyclic portion. These non-RGD peptides display surprisingly potent antagonist activity despite the lack of the consensus binding sequence Arg-Gly-Asp, and present opportunities for selective targeting to the .alpha..sub.v .beta..sub.3 receptor. Pharmaceutical compositions and methods of use are also disclosed. The therapeutic uses for the inventive peptides include treating diseases involving .alpha..sub.v .beta..sub.3 receptors such as cancer, osteoporosis, restenosis, and angiogenic-based diseases.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 14, 1998
    Assignee: IXSYS, Incorporated
    Inventors: Michael A. Palladino, Bruce A. Lee, William D. Huse, Judith A. Varner
  • Sevenmer cyclic peptide inhibitors of diseases involving .alpha..sub.v .beta..sub.3
    Patent number: 5767071
    Abstract: The present invention includes non-RGD, nine amino acid cyclic peptides that inhibit the function of the integrin receptor, .alpha..sub.v .beta..sub.3. These peptides display surprisingly potent antagonist activity despite the lack of the consensus binding sequence Arg-Gly-Asp, and present opportunities for selective targeting to the .alpha..sub.v .beta..sub.3 receptor. Pharmaceutical compositions and methods of use are also disclosed. The therapeutic uses for the inventive peptides include treating diseases involving .alpha..sub.v .beta..sub.3 receptors such as osteoporosis, restenosis, and angiogenic-based diseases, including cancer, arthritis, and diabetic retinopathy.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 16, 1998
    Assignee: IXSYS Incorporated
    Inventors: Michael A. Palladino, Bruce A. Lee, William D. Huse, Judith A. Varner